# Antihypertensive Effect of Different Doses of Rostafuroxin in Comparison With Losartan

Study · id `cardio:ct-nct03217825` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03217825](<https://clinicaltrials.gov/study/NCT03217825>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03217825

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 240 participants.

## Technical summary

Registry record NCT03217825. Randomized; triple masking; primary purpose treatment. Start 2015-12 (actual); primary completion 2018-02-08 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 240 participants (enrolled count; ClinicalTrials.gov record NCT03217825, source copy `cardio:ctgov-nct03217825-2023-02-21`, retrieved 2026-10-26)
- Started: 2015-12 (actual) (ClinicalTrials.gov record NCT03217825, source copy `cardio:ctgov-nct03217825-2023-02-21`, retrieved 2026-10-26)
- Primary completion: 2018-02-08 (actual) (ClinicalTrials.gov record NCT03217825, source copy `cardio:ctgov-nct03217825-2023-02-21`, retrieved 2026-10-26)
- Completion: 2018-02-08 (actual) (ClinicalTrials.gov record NCT03217825, source copy `cardio:ctgov-nct03217825-2023-02-21`, retrieved 2026-10-26)
- Countries: Taiwan (ClinicalTrials.gov record NCT03217825, source copy `cardio:ctgov-nct03217825-2023-02-21`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03217825-2023-02-21`, retrieved 2026-10-26)

## The registry's words

- Brief title: Antihypertensive Effect of Different Doses of Rostafuroxin in Comparison With Losartan
- Condition: Hypertension
- Intervention (Drug): Rostafuroxin
- Intervention (Drug): Losartan
- Lead sponsor: Windtree Therapeutics
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry intervention name matches this record: Losartan (`cardio:losartan`)

### Other papers using this trial's data

- Registry lists this paper as a reference of type result; PubMed dates it on or after the trial start and types it as a trial report, neither its types nor its title mark it as a protocol, a review or a comment, the paper names no other trial in place of this one, and PubMed shows no retraction or expression of concern; it is not marked as the trial's main report: Antihypertensive treatment guided by genetics: PEARL-HT, the randomized proof-of-concept trial comparing rostafuroxin with losartan (`cardio:pubmed-33649520`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 48fa2797242536220b5cf88f43c9b780b29c715979e5b1fd18c79f7fc7e50552
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
